The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.

The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.

The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.

Opdivo is approved for a number of cancers, including lung cancer.